Cover Image
市場調查報告書

難治性慢性淋巴性白血病:開發中產品分析

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251633
出版日期 內容資訊 英文 266 Pages
訂單完成後即時交付
價格
Back to Top
難治性慢性淋巴性白血病:開發中產品分析 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016
出版日期: 2016年11月23日 內容資訊: 英文 266 Pages
簡介

對治療毫無反應的白血病,便稱之為難治性慢性淋巴性白血病(CLL)。常見的症狀有發燒及感染、異常出血、呼吸困難、體重減少、淋巴結腫等症狀。治療方法包含有幹細胞移植/骨髓移植。

本報告提供難治性慢性淋巴性白血病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

難治性慢性淋巴性白血病 (CLL)概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

難治性慢性淋巴性白血病 (CLL):企業開發中的治療藥

難治性慢性淋巴性白血病 (CLL):大學/機關研究中的治療藥

難治性慢性淋巴性白血病 (CLL):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

難治性慢性淋巴性白血病 (CLL):企業開發中的產品

難治性慢性淋巴性白血病 (CLL):大學/機關研究中的產品

難治性慢性淋巴性白血病 (CLL的)治療藥的開發企業

  • 4SC AG
  • AbbVie Inc.
  • Arno Therapeutics, Inc.
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cellular Biomedicine Group, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hutchison MediPharma Limited
  • ImmunoGen, Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • Infinity Pharmaceuticals, Inc.
  • Innate Pharma S.A.
  • Juno Therapeutics Inc.
  • Karyopharm Therapeutics, Inc.
  • Les Laboratoires Servier SAS
  • LFB S.A.
  • Lymphocyte Activation Technologies, S.A.
  • Medicenna Therapeutics, Inc.
  • Millennium Pharmaceuticals, Inc.
  • MorphoSys AG
  • Novartis AG
  • Oncternal Therapeutics, Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Portola Pharmaceuticals, Inc.
  • Sanofi
  • TG Therapeutics, Inc.
  • Threshold Pharmaceuticals, Inc.
  • Tragara Pharmaceuticals, Inc.

難治性慢性淋巴性白血病 (CLL):治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

難治性慢性淋巴性白血病 (CLL):最近的開發平台趨勢

難治性慢性淋巴性白血病 (CLL):暫停中的計劃

難治性慢性淋巴性白血病 (CLL):開發中止的產品

難治性慢性淋巴性白血病 (CLL):產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8687IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016, provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Leukemia that does not responded to treatment is called refractory chronic lymphocytic leukemia. Symptoms include fever and infection, abnormal bleeding, shortness of breath, weight loss and swelling of lymph nodes. Treatment includes stem cell transplantation or bone marrow transplantation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 21, 16 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Refractory Chronic Lymphocytic Leukemia (CLL).

Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 5
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Refractory Chronic Lymphocytic Leukemia (CLL) Overview 8
  • Therapeutics Development 9
  • Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Overview 9
  • Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 10
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 13
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 14
  • Late Stage Products 14
  • Clinical Stage Products 15
  • Early Stage Products 16
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 17
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 20
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 21
  • 4SC AG 21
  • AbbVie Inc 22
  • Arno Therapeutics, Inc. 23
  • Astellas Pharma Inc. 24
  • Astex Pharmaceuticals Inc 25
  • Boehringer Ingelheim GmbH 26
  • Bristol-Myers Squibb Company 27
  • Celgene Corporation 28
  • Cellular Biomedicine Group, Inc. 29
  • F. Hoffmann-La Roche Ltd. 30
  • Gilead Sciences, Inc. 31
  • Hutchison MediPharma Limited 32
  • ImmunoGen, Inc. 33
  • Immunomedics, Inc. 34
  • Incyte Corporation 35
  • Innate Pharma S.A. 36
  • Juno Therapeutics Inc. 37
  • Karyopharm Therapeutics, Inc. 38
  • LFB S.A. 39
  • Lymphocyte Activation Technologies, S.A. 40
  • Medicenna Therapeutics, Inc. 41
  • Millennium Pharmaceuticals Inc 42
  • MorphoSys AG 43
  • Novartis AG 44
  • Oncternal Therapeutics, Inc. 45
  • Ono Pharmaceutical Co., Ltd. 46
  • Portola Pharmaceuticals, Inc. 47
  • Sanofi 48
  • Tragara Pharmaceuticals, Inc. 49
  • Verastem, Inc. 50
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 51
  • Assessment by Monotherapy Products 51
  • Assessment by Combination Products 52
  • Assessment by Target 53
  • Assessment by Mechanism of Action 56
  • Assessment by Route of Administration 59
  • Assessment by Molecule Type 61
  • Drug Profiles 63
  • (dezapelisib + itacitinib adipate) - Drug Profile 63
  • 4SC-202 - Drug Profile 64
  • acalabrutinib - Drug Profile 66
  • ACP-319 - Drug Profile 69
  • afuresertib hydrochloride - Drug Profile 70
  • AGS-67E - Drug Profile 73
  • AR-42 - Drug Profile 75
  • AT-7519 - Drug Profile 77
  • atezolizumab - Drug Profile 80
  • BI-836826 - Drug Profile 94
  • BMS-986016 - Drug Profile 96
  • buparlisib hydrochloride - Drug Profile 98
  • CBM-C19.1 - Drug Profile 103
  • CBM-C20.1 - Drug Profile 104
  • CC-122 - Drug Profile 106
  • Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile 108
  • Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile 109
  • cerdulatinib - Drug Profile 110
  • duvelisib - Drug Profile 113
  • HMPL-523 - Drug Profile 123
  • idelalisib - Drug Profile 125
  • IMGN-529 - Drug Profile 133
  • IMMU-114 - Drug Profile 135
  • JCAR-014 - Drug Profile 137
  • JCAR-015 - Drug Profile 140
  • lirilumab - Drug Profile 144
  • MDNA-56 - Drug Profile 148
  • monalizumab - Drug Profile 149
  • MOR-208 - Drug Profile 152
  • nivolumab - Drug Profile 157
  • obinutuzumab - Drug Profile 183
  • PCAR-019 - Drug Profile 190
  • PCAR-119 - Drug Profile 191
  • pilaralisib - Drug Profile 192
  • S-055746 - Drug Profile 195
  • selinexor - Drug Profile 196
  • spebrutinib besylate - Drug Profile 215
  • TAK-659 - Drug Profile 217
  • TG-02 - Drug Profile 218
  • tisagenlecleucel-T - Drug Profile 221
  • ublituximab - Drug Profile 226
  • UC-961 - Drug Profile 233
  • ulocuplumab - Drug Profile 235
  • urelumab - Drug Profile 236
  • venetoclax - Drug Profile 238
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 247
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 249
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 250
  • Featured News & Press Releases 250
  • Appendix 262
  • Methodology 262
  • Coverage 262
  • Secondary Research 262
  • Primary Research 262
  • Expert Panel Validation 262
  • Contact Us 262
  • Disclaimer 263

List of Tables

  • Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H2 2016 12
  • Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2016 13
  • Number of Products under Development by Companies, H2 2016 14
  • Number of Products under Development by Companies, H2 2016 (Contd..1) 15
  • Number of Products under Investigation by Universities/Institutes, H2 2016 16
  • Comparative Analysis by Late Stage Development, H2 2016 17
  • Comparative Analysis by Clinical Stage Development, H2 2016 18
  • Comparative Analysis by Early Stage Development, H2 2016 19
  • Products under Development by Companies, H2 2016 20
  • Products under Development by Companies, H2 2016 (Contd..1) 21
  • Products under Development by Companies, H2 2016 (Contd..2) 22
  • Products under Investigation by Universities/Institutes, H2 2016 23
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H2 2016 24
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H2 2016 25
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics, Inc., H2 2016 26
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H2 2016 27
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 28
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 29
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H2 2016 30
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H2 2016 31
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group, Inc., H2 2016 32
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 33
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences, Inc., H2 2016 34
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H2 2016 35
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H2 2016 36
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H2 2016 37
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H2 2016 38
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma S.A., H2 2016 39
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H2 2016 40
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 41
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H2 2016 42
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies, S.A., H2 2016 43
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Medicenna Therapeutics, Inc., H2 2016 44
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 45
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H2 2016 46
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H2 2016 47
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics, Inc., H2 2016 48
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 49
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H2 2016 50
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H2 2016 51
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H2 2016 52
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Verastem, Inc., H2 2016 53
  • Assessment by Monotherapy Products, H2 2016 54
  • Assessment by Combination Products, H2 2016 55
  • Number of Products by Stage and Target, H2 2016 57
  • Number of Products by Stage and Mechanism of Action, H2 2016 60
  • Number of Products by Stage and Route of Administration, H2 2016 63
  • Number of Products by Stage and Molecule Type, H2 2016 65
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2016 250
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H2 2016 251
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H2 2016 252

List of Figures

  • Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H2 2016 12
  • Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2016 13
  • Number of Products under Development by Companies, H2 2016 14
  • Comparative Analysis by Late Stage Development, H2 2016 17
  • Comparative Analysis by Clinical Stage Development, H2 2016 18
  • Assessment by Monotherapy Products, H2 2016 54
  • Number of Products by Top 10 Targets, H2 2016 56
  • Number of Products by Stage and Top 10 Targets, H2 2016 56
  • Number of Products by Top 10 Mechanism of Actions, H2 2016 59
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 59
  • Number of Products by Routes of Administration, H2 2016 62
  • Number of Products by Stage and Routes of Administration, H2 2016 62
  • Number of Products by Molecule Types, H2 2016 64
  • Number of Products by Stage and Molecule Types, H2 2016 64
Back to Top